InMed Pharmaceuticals (INM) Other Accumulated Expenses (2021 - 2023)

InMed Pharmaceuticals' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $2.3 million for Q1 2023.

• On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $2.3 million in Q1 2023; TTM through Mar 2023 was $2.3 million, a N/A change from a year earlier, with the FY2022 full-year figure at $3.2 million, up 43.6% from the prior year.
• Other Accumulated Expenses slipped to $2.3 million in Q1 2023 per INM's latest filing, from $2.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.3 million in Q3 2022 and bottomed at $2.2 million in Q2 2021.
• The 3-year median for Other Accumulated Expenses is $2.4 million (2022), against an average of $2.7 million.
• Biggest YoY gain for Other Accumulated Expenses was 43.6% in 2022; the steepest drop was 43.6% in 2022.
• Year by year, Other Accumulated Expenses stood at $2.2 million in 2021, then increased by 8.37% to $2.4 million in 2022, then fell by 5.46% to $2.3 million in 2023.
• Per Business Quant, the three latest INM Other Accumulated Expenses figures stand at $2.3 million (Q1 2023), $2.4 million (Q4 2022), and $3.3 million (Q3 2022).